The results of the CD8+ T cell-mediated MC38 cell killing assay indicates that RGE efficiently enhanced the activation of tumor-infiltrating hPD-1-expressing CD8+ T cell immune function through inhibition of the hPD-1/hPD-L1 interaction. This evidence concerns the gene CD8A and neoplasm.